CN · biotech · immunology · inflammation
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series C · May 2026 · $50M
OrbiMed lead, LAV, Oriza Holdings, Cenova Capital, Shenzhen Capital Group, TCG Crossover
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.